Making Chemotherapy Toxicity Palatable by What You Put or Don’t on Dinner Plate

Watching what we eat and how much we eat may be an effective tool to manage the toxicity of chemotherapy drugs says this month's online article in the New England Journal of Medicine.

How the Evil Doctor Doofenshmirtz is Bringing Cancer Metabolic Addiction to the Tri-State Area

A Senior VP of a Bay Area cancer biotech's R&D recently gave a spin to an old saying and commented, “the beatings will continue until the patient body's morale will improve,” and he added, “the beating will now come through cancer cell metabolism."  

Emerging Target, “Cell Metabolism”: From Boondocks to Harvard Square, Boston

The emergence of “cancer energy metabolism” as one of the promising targets, is affirmed by the two significant Pharma deals this year:

Mining aminoacyl tRNA synthases (aaRSs) for anti-angiogenic factors

Aminoacyl tRNA synthases (aaRSs) are ancient catalytic enzymes that catalyze the first step in protein synthesis, transfer of amino acid to its cognate tRNA, something that we learned years ago in Stryer’s Biochemistry.  But, these enzymes are also moonlighting proteins, with alternate splice forms or natural proteolytic fragments, acting as cytokines, angiogenic factors or angiostatic factors. The one that caught my eye was tryptophanyl-tRNA synthase (TrpRS) fragment which is antiangiogenic and is in clinical development for retinal diseases [...][...].